Holen Sie sich die Stockscreener-App
41.64
0.60%
0.25
Vorhandelsmarkt:
42.39
0.75
+1.80%
Schlusskurs vom Vortag:
$41.39
Offen:
$41.01
24-Stunden-Volumen:
529.53K
Relative Volume:
0.58
Marktkapitalisierung:
$2.11B
Einnahmen:
$534.53M
Nettoeinkommen (Verlust:
$-11.45M
KGV:
-172.71
EPS:
-0.2411
Netto-Cashflow:
$48.28M
1W Leistung:
+7.54%
1M Leistung:
+21.47%
6M Leistung:
+9.98%
1J Leistung:
+17.93%
1-Tages-Spanne:
$41.01
$42.22
1-Wochen-Bereich:
$37.98
$42.22
52-Wochen-Spanne:
$25.36
$43.18
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
41.64 | 1.89B | 534.53M | -11.45M | 48.28M | -0.2411 |
ISRG
Intuitive Surgical Inc
|
393.38 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.63 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
73.63 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
220.05 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.81 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-02-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
Inspire Medical Systems appoints Michael H. Carrel to its board - Medical Buyer
AtriCure, Inc. (ATRC) Beat Earnings Estimates. Here’s What Could Drive ATRC Stock Next - Yahoo Finance
AtriCure, Inc. (ATRC) Q2 2026 10-Q Report: Financial Performance, Earnings, and Stockholder Updates - Minichart
AtriCure CEO Carrel joins Inspire Medical board of directors - MassDevice
AtriCure, Inc. 2026: Revenue $153.6M, EPS $0.18— 10-Q Summary - TradingView
[10-Q] AtriCure, Inc. Quarterly Earnings Report - Stock Titan
Inspire Medical Systems adds AtriCure CEO to board - Investing.com
Inspire Medical Systems adds AtriCure CEO to board By Investing.com - Investing.com South Africa
AtriCure’s Profitability Inflection and 2026 Guidance Could Be A Game Changer For AtriCure (ATRC) - simplywall.st
Inspire's New Director Comes From AtriCure, Which Helped Over 1M Patients - Stock Titan
AtriCure Inc (ATRC) Institutional Confidence - TradingKey
AtriCure Inc (ATRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ATRC|AtriCure Inc|Price:35.040|Chg%:+2.040 - TradingKey
AtriCure Inc (ATRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AtriCure Inc (ATRC) Balance Sheet - TradingKey
AtriCure Inc (ATRC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AtriCure Inc (ATRC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atricure (ATRC) - The Globe and Mail
Atricure (ATRC) Receives a Buy from Stifel Nicolaus - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH) - The Globe and Mail
BTIG Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $45 - Moomoo
AtriCure Reports Second Quarter 2026 Financial Results - BioSpace
AtriCure revenue up 12.8% to USD 153.6M in Q2 2026 - Medical Buyer
AtriCure Inc (ATRC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AtriCure Inc (ATRC) Q2 2026 Earnings Call Highlights: Strong Rev - GuruFocus
AtriCure Inc (ATRC) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Profitability ... - Yahoo Finance
AtriCure 2Q Net $8.96M >ATRC - Moomoo
AtriCure (ATRC) Reports Strong Q2 2026 Results with Revenue Grow - GuruFocus
AtriCure Releases Q2 2026 Financial Results - AlphaStreet
AtriCure Q2 Swings to Adjusted Earnings, Revenue Rises - Moomoo
Transcript : AtriCure, Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
AtriCure Q2 Earnings Call Highlights - TradingView
Is AtriCure Inc (ATRC) Undervalued After Q2 Earnings Beat? EPS $0.18 on Revenue of $153.6M -- GF Score 78/100 - GuruFocus
Earnings call transcript: AtriCure tops Q2 2026 estimates, shares fall after hours - Investing.com
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
AtriCure surges 3% on earnings beat and raised guidance - Investing.com India
AtriCure surges 3% on earnings beat and raised guidance By Investing.com - Investing.com South Africa
AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue - ChartMill
ATRICURE ($ATRC) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Q2 2026 AtriCure Inc Earnings Call Transcript - GuruFocus
AtriCure set to report earnings as competitive threat looms - Investing.com UK
(ATRC) AtriCure Expects 2026 Adjusted EPS Range $0.24-$0.32, vs. FactSet Est of $0.12 - marketscreener.com
(ATRC) AtriCure Expects 2026 Revenue Range $602M-$610M, vs. FactSet Est of $604.6M - marketscreener.com
GUIDANCE: (ATRC) AtriCure Expects 2026 Adjusted EPS Range $0.24-$0.32, Vs. FactSet Est of $0.12 - Moomoo
AtriCure: Q2 Earnings Snapshot - The Daily Independent
Earnings Flash (ATRC) AtriCure, Inc. Reports Q2 Revenue $153.6M, vs. FactSet Est of $151.8M - marketscreener.com
Earnings Flash (ATRC) AtriCure, Inc. Posts Q2 Adjusted EPS $0.18 per Share, vs. FactSet Est of $0.00 - marketscreener.com
AtriCure reports Q2 2026 revenue $153.6M, net income $9.0M and adjusted EBITDA $27.3M - TradingView
BRIEF-AtriCure Q2 Adjusted EPS USD 0.18 Vs. IBES Estimate USD 0 - TradingView
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atricure Inc-Aktie (ATRC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Yuen Maggie | Director |
Aug 05 '26 |
Sale |
38.42 |
3,500 |
134,470 |
14,015 |
1.37%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):